Rhodes Jennifer J 4

What Happened
Jennifer J. Rhodes, Executive Vice President and Chief Legal Officer of ACADIA Pharmaceuticals (ACAD), received two equity awards on March 6, 2026: 90,691 stock option shares (derivative award) and 26,382 restricted stock units (RSUs). Both grants show an acquisition price of $0.00 (no cash paid). These are compensation awards (not open‑market purchases or sales).

Key Details

• Transaction date: 2026-03-06; Form 4 filed: 2026-03-10 (filed within the required reporting window).
• Grant details: 90,691 stock option shares and 26,382 RSUs; both reported as acquisition (code A) at $0.00.
• Shares owned after transaction: not reported on the Form 4 (or not included in the filing).
• Footnotes: F1 — 25% of the stock option vests on March 6, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter. F2 — each RSU represents a contingent right to receive one share of common stock. F3 — RSUs vest in four equal annual installments beginning March 6, 2027.
• Transaction type: awards/compensation (derivative grants), not a sale or market purchase.

Context
These awards are standard executive compensation grants. The stock option award has a multi-year vesting schedule (initial 25% after one year, then monthly over three years); the RSUs vest annually over four years beginning March 6, 2027. Because these are grants (derivative awards) and no shares were sold immediately, they should be viewed as compensation rather than an immediate market buying/selling signal.